Cargando…

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score

The Psoriasis Area and Severity Index (PASI) is the most widely used clinical measure in clinical trials to assess disease severity of plaque psoriasis. However, the PASI is not a precise measure of severity with less precision when the regional area of involvement is < 10% of the BSA of a specif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papp, Kim A., Lebwohl, Mark G., Kircik, Leon H., Pariser, David M., Strober, Bruce, Krueger, Gerald G., Berk, David R., Navale, Lynn, Higham, Robert C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322185/ https://www.ncbi.nlm.nih.gov/pubmed/34236691 http://dx.doi.org/10.1007/s13555-021-00572-2

Ejemplares similares

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
por: Maravilla-Herrera, Paulina, et al.
Publicado: (2023)

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
por: Stein Gold, Linda, et al.
Publicado: (2022)

PASI AND PQOL-12 SCORE IN PSORIASIS: IS THERE ANY CORRELATION?
por: Shankar, Vikas, et al.
Publicado: (2011)

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses
por: Baker, Erica L., et al.
Publicado: (2012)

A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm
por: Strober, Bruce, et al.
Publicado: (2021)

Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response
por: Sawyer, L.M., et al.
Publicado: (2018)

Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
por: Wu, Albert G., et al.
Publicado: (2020)

Glycomics@ExPASy: Bridging the Gap
por: Mariethoz, Julien, et al.
Publicado: (2018)

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
por: Van Voorhees, A.S., et al.
Publicado: (2021)

Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis
por: Choi, Sungjun, et al.
Publicado: (2022)

Psoriasis Area and Severity Index (PASI) Objectivisation by Flow Cytometry Analysis of Major Lymphocytes Subsets
por: Zecevic-Pasic, Lamija, et al.
Publicado: (2023)

Both Educational Lectures and Reference Photographs Are Necessary to Improve the Accuracy and Reliability of Psoriasis Area and Severity Index (PASI) Assessment: Results from Korean Nation-Wide PASI Educational Workshop
por: Choi, Chong Won, et al.
Publicado: (2018)

PASI studies new states of matter
Publicado: (2002)

PASI studies new states of matter
por: Rafelski, Johann
Publicado: (2002)

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis
por: Valenzuela, Fernando, et al.
Publicado: (2015)

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies
por: Thurston, Archie W., et al.
Publicado: (2022)

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
por: Sawyer, Laura M., et al.
Publicado: (2019)

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients
por: Hägg, David, et al.
Publicado: (2017)

ExPASy: SIB bioinformatics resource portal
por: Artimo, Panu, et al.
Publicado: (2012)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
por: Armstrong, April W., et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
por: Gottlieb, AB, et al.
Publicado: (2012)

The effect of moving cupping on psoriasis vulgaris and its influence on PASI score: A protocol for systematic review and meta-analysis
por: Yunbo, Wu, et al.
Publicado: (2021)

Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment()
por: da Silva, Maria Flávia Pereira, et al.
Publicado: (2013)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Automated, computer-guided PASI measurements by digital image analysis versus conventional physicians’ PASI calculations: study protocol for a comparative, single-centre, observational study
por: Fink, Christine, et al.
Publicado: (2018)

Le PASI étudie de nouveaux états de la matière
Publicado: (2002)

PASI: A novel pathway method to identify delicate group effects
por: Jaakkola, Maria K., et al.
Publicado: (2018)

Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?
por: Kirsten, Natalia, et al.
Publicado: (2021)

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Menter, A., et al.
Publicado: (2016)

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
por: Pariser, David, et al.
Publicado: (2017)

Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2021)

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
por: Papp, K.A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_is8naucfkdckji03o2ntib1at0